Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial

Anita Hill, MBChB (Hons), PhD, Wynne Weston-Davies, MB FRCS, Miles Nunn, PhD, Tadeusz Robak, MD PhD, Jerzy Windyga, MD, Andrzej Hellmann, MD PhD DSc, Austin G. Kulasekararaj, MBBS, MD MRCP, FRCPath, Agniezka Piekarska, Anna Szmigielska-Kaplon, Morag Griffin, Talha Munir

Blood (2017) 130 (Supplement 1): 4747.

https://doi.org/10.1182/blood.V130.Suppl_1.4747.4747

Published: 2017

Journal Articles

Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A

Yesim G. Dargaud, MDPhD, Robert Klamroth, Luminita Rusen, MD, Jerzy Windyga, MD, Johann Bichler, PhD, Sigurd Knaub, Claude Negrier, MD

Blood (2016) 128 (22): 1410.

https://doi.org/10.1182/blood.V128.22.1410.1410

Published: 2016

Journal Articles

Pharmacodynamic Profile of a Recombinant ADAMTS13 (BAX930) in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome (USS))

Marie Scully, Paul Knoebl, MD, Karim Kentouche, Lawrence Rice, MD, Jerzy Windyga, MD, Reinhard Schneppenheim, Johanna A Kremer Hovinga, MD PhD, Michiko Kajiwara, Caterina Maggiore, Jennifer Doralt, Leah Martell, Bruce M. Ewenstein

Blood (2016) 128 (22): 135.

https://doi.org/10.1182/blood.V128.22.135.135

Published: 2016

Journal Articles

Pharmacokinetic Profile of Nonacog Gamma (recombinant factor IX) in Previously-Treated Patients with Severe or Moderately Severe Hemophilia B

Jerzy Windyga, MD, Toshko Jelev Lissitchkov, MD, Miranda Chapman, Srilatha D. Tangada, PhD, Nirjhar Chatterjee, MD

Blood (2016) 128 (22): 4978.

https://doi.org/10.1182/blood.V128.22.4978.4978

Published: 2016

Journal Articles

Feiba Global Outcome Study (FEIBA-GO): Long-Term Real World Data on Apcc (Feiba R ) in Patients with Inhibitors. First Demographic Data

Ana Rosa Cid, MD, Carmen Escuriola, MD, Cedric R. Hermans, MD PhD MRCP, Pal André Holme, PhD MD, Claude Negrier, MD, Savita Rangarajan, Angiola Rocino, Jerzy Windyga, MD, Alessandro Gringeri, MD MSc, Roberto Crea, DVM, MSc

Blood (2016) 128 (22): 5038.

https://doi.org/10.1182/blood.V128.22.5038.5038

Published: 2016

Journal Articles

Recombinant Factor IX in Surgical Management of Hemostasis in Hemophilia B Patients: A Prospective Clinical Trial

Jerzy Windyga, MD, Toshko Jelev Lissitchkov, MD, Vasily Mamonov, MD, Miranda Chapman, Srilatha D. Tangada, PhD, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 2585.

https://doi.org/10.1182/blood.V128.22.2585.2585

Published: 2016

Journal Articles

Pharmacokinetics, Efficacy and Safety of BAX326, a Novel Recombinant Factor IX: A Prospective, Controlled, Multicenter Study in Previously Treated Patients with Severe (FIX Level < 1%) or Moderately Severe (FIX Level ≤ 2%) Hemophilia B.

Jerzy Windyga, MD, PhD, Toshko Lissitchkov, MD, PhD, Oleksandra Stasyshyn, MD, Vasily Mamonov, MD, Luminita Rusen, MD, PhD, José Luis Lamas, MD, Myungshin Oh, PhD, Miranda Chapman, Sandor Fritsch, PhD, Borislava G Pavlova, PhD, Wing Yen Wong, MD, Brigitt E. Abbuehl, MD

Blood (2012) 120 (21): 2222.

https://doi.org/10.1182/blood.V120.21.2222.2222

Published: 2012

Journal Articles

Prophylactic Dosing of Anti-Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors: Results of the Pro-FEIBA Study

Cindy A. Leissinger, MD, Eric Berntorp, MD, Chiara Biasioli, MD, Shannon Carpenter, MD, MS, Hyejin Jo, MS, Kaan Kavakli, MD, Claude Negrier, MD, Angiola Rocino, MD, Jerzy Windyga, MD, Bulent Zulfikar, MD, Alessandro Gringeri, MD

Blood (2010) 116 (21): 720.

https://doi.org/10.1182/blood.V116.21.720.720

Published: 2010

Journal Articles

BDDrFVIII [moroctocog alfa (AF-CC), Xyntha] for Surgical Hemostasis in Patients with Hemophilia A: Results from a Pivotal Study.

Jerzy Windyga, MD, PhD, Luminita Rusen, MD, PhD, Amanda C. O’Brien, Brooke Hayward, SM, Steven Arkin, MD, David A. Roth, MD

Blood (2008) 112 (11): 1229.

https://doi.org/10.1182/blood.V112.11.1229.1229

Published: 2008

Journal Articles

Efficacy and Safety of ReFacto AF for Surgical Hemostasis in Previously Treated Patients with Severe Hemophilia A.

Jerzy Windyga, MD, PhD, Luminita Rusen, MD, Mona El-Hashimy, MD, David A. Roth, MD, Steven Arkin, MD

Blood (2007) 110 (11): 3960.

https://doi.org/10.1182/blood.V110.11.3960.3960

Published: 2007

Journal Articles

Tracking Factor VIII-Specific Memory B Cells in Hemophilia A Patients with Factor VIII Inhibitors.

Irene Lang, Jerzy Windyga, MD, Anna Klukowska, MD, Josenato Ilas, Hans Peter Schwarz, MD, Birgit M. Reipert, PhD

Blood (2006) 108 (11): 1016.

https://doi.org/10.1182/blood.V108.11.1016.1016

Published: 2006

Journal Articles

Clinical Efficacy and Safety of Wilate ® , A New Generation, High-Purity VWF/FVIII-Concentrate with Optimized Pharmacokinetic Properties in the Treatment of Von Willebrand Disease.

Jerzy Windyga, MD, Antoaneta Zarkova, MD, Olaf Walter, MD, Guenter Auerswald, MD

Blood (2005) 106 (11): 1795.

https://doi.org/10.1182/blood.V106.11.1795.1795

Published: 2005

NARROW

Coversin, a Novel C5 Complement Inhibitor, Is Safe and Effective in the Treatment of PNH: Results of a Phase II Clinical Trial

Thrombin Generation and Bleeding Phenotype during Personalized Prophylaxis with Recombinant Human FVIII in Previously Treated Patients with Severe Hemophilia A

Pharmacodynamic Profile of a Recombinant ADAMTS13 (BAX930) in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome (USS))

Pharmacokinetic Profile of Nonacog Gamma (recombinant factor IX) in Previously-Treated Patients with Severe or Moderately Severe Hemophilia B

Feiba Global Outcome Study (FEIBA-GO): Long-Term Real World Data on Apcc (Feiba R ) in Patients with Inhibitors. First Demographic Data

Recombinant Factor IX in Surgical Management of Hemostasis in Hemophilia B Patients: A Prospective Clinical Trial

Pharmacokinetics, Efficacy and Safety of BAX326, a Novel Recombinant Factor IX: A Prospective, Controlled, Multicenter Study in Previously Treated Patients with Severe (FIX Level < 1%) or Moderately Severe (FIX Level ≤ 2%) Hemophilia B.

Prophylactic Dosing of Anti-Inhibitor Coagulant Complex (FEIBA) Reduces Bleeding Frequency In Hemophilia A Patients with Inhibitors: Results of the Pro-FEIBA Study

BDDrFVIII [moroctocog alfa (AF-CC), Xyntha] for Surgical Hemostasis in Patients with Hemophilia A: Results from a Pivotal Study.

Efficacy and Safety of ReFacto AF for Surgical Hemostasis in Previously Treated Patients with Severe Hemophilia A.

Tracking Factor VIII-Specific Memory B Cells in Hemophilia A Patients with Factor VIII Inhibitors.

Clinical Efficacy and Safety of Wilate ® , A New Generation, High-Purity VWF/FVIII-Concentrate with Optimized Pharmacokinetic Properties in the Treatment of Von Willebrand Disease.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only